FDA Panel Sees No Heart-Safety Advantage With Naproxen
Some studies had suggested naproxen (Aleve) might pose less of a threat than other painkillersContinue Reading
Some studies had suggested naproxen (Aleve) might pose less of a threat than other painkillersContinue Reading
Marketed as Onglyza and Kombiglyze XR, drug appears to have no effect on heart attack or stroke riskContinue Reading
Researchers tallied costs in health care, lost productivity over 14 yearsContinue Reading
Reports received from 3 states, FDA saysContinue Reading
Studies suggest naproxen (Aleve) may pose less of a threatContinue Reading
School systems bear the brunt, not parents, researchers findContinue Reading
But the impact on moderate drinkers would be minimal, researchers sayContinue Reading
Newer heating units use one-third less wood and produce 60 percent less air pollution than older modelsContinue Reading
For people with less education, study suggests attitude makes a difference in lifespanContinue Reading
Doctors realized patient’s mysterious symptoms resembled those of a character on the medical dramaContinue Reading
© 2021 WeeklyMD.com - All Rights Reserved.